Cargando…
An Economic Analysis of Transjugular Intrahepatic Portosystemic Covered Stent Shunt for Variceal Bleeding and Refractory Ascites in a Spanish Setting
INTRODUCTION: The primary aim is to estimate the cost-effectiveness of transjugular intrahepatic portosystemic stent shunt (TIPSS) in two indications from a Spanish perspective. Firstly, as pre-emptive treatment for patients with acute variceal bleeding (indication 1) compared with endoscopic band l...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10272260/ https://www.ncbi.nlm.nih.gov/pubmed/37160834 http://dx.doi.org/10.1007/s12325-023-02517-x |
_version_ | 1785059455978700800 |
---|---|
author | Bañares, Rafael Albillos, Agustín Nakum, Mitesh Gea, Salvador Varghese, Angel Green, William |
author_facet | Bañares, Rafael Albillos, Agustín Nakum, Mitesh Gea, Salvador Varghese, Angel Green, William |
author_sort | Bañares, Rafael |
collection | PubMed |
description | INTRODUCTION: The primary aim is to estimate the cost-effectiveness of transjugular intrahepatic portosystemic stent shunt (TIPSS) in two indications from a Spanish perspective. Firstly, as pre-emptive treatment for patients with acute variceal bleeding (indication 1) compared with endoscopic band ligation plus drug therapy. Secondly, to treat refractory ascites (indication 2) compared with large volume paracentesis. METHODS: A two-state (alive and dead) Markov model was developed to capture the costs and health impact for the two indications over a 2-year time horizon with monthly cycles. In the alive state, patients could experience adverse event(s), associated with costs and disutility, such as recurrent variceal bleeding, ascites, and hepatic encephalopathy. Discount rates of 3% for utilities and costs and a cost-effectiveness threshold of €25,000 per QALY were applied. RESULTS: In the base case analysis, TIPSS was estimated to be cost-effective as a pre-emptive treatment for indication 1 (incremental cost and QALYs of − €230 and 0.211, respectively). TIPSS also remained cost-effective (€16,819/QALY) in a conservative scenario analysis, conducted with an alternate source for clinical parameters. The key drivers of the outcomes were survival for the comparator arm, mean band ligation outpatient procedures, and TIPSS treatment costs. TIPSS was estimated to dominate the comparator for indication 2 (incremental cost and QALYs of − €25,687 and 0.531, respectively). The key drivers of the outcomes were monthly paracentesis sessions and cost per inpatient stay for those undergoing paracentesis. CONCLUSIONS: TIPSS is likely to be a cost-effective and a cost-saving treatment in patients with cirrhosis in indications 1 and 2, compared with standard treatments. The analyses estimate clinical benefits along with reduced healthcare costs from avoided downstream resource consumption. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s12325-023-02517-x. |
format | Online Article Text |
id | pubmed-10272260 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Springer Healthcare |
record_format | MEDLINE/PubMed |
spelling | pubmed-102722602023-06-17 An Economic Analysis of Transjugular Intrahepatic Portosystemic Covered Stent Shunt for Variceal Bleeding and Refractory Ascites in a Spanish Setting Bañares, Rafael Albillos, Agustín Nakum, Mitesh Gea, Salvador Varghese, Angel Green, William Adv Ther Original Research INTRODUCTION: The primary aim is to estimate the cost-effectiveness of transjugular intrahepatic portosystemic stent shunt (TIPSS) in two indications from a Spanish perspective. Firstly, as pre-emptive treatment for patients with acute variceal bleeding (indication 1) compared with endoscopic band ligation plus drug therapy. Secondly, to treat refractory ascites (indication 2) compared with large volume paracentesis. METHODS: A two-state (alive and dead) Markov model was developed to capture the costs and health impact for the two indications over a 2-year time horizon with monthly cycles. In the alive state, patients could experience adverse event(s), associated with costs and disutility, such as recurrent variceal bleeding, ascites, and hepatic encephalopathy. Discount rates of 3% for utilities and costs and a cost-effectiveness threshold of €25,000 per QALY were applied. RESULTS: In the base case analysis, TIPSS was estimated to be cost-effective as a pre-emptive treatment for indication 1 (incremental cost and QALYs of − €230 and 0.211, respectively). TIPSS also remained cost-effective (€16,819/QALY) in a conservative scenario analysis, conducted with an alternate source for clinical parameters. The key drivers of the outcomes were survival for the comparator arm, mean band ligation outpatient procedures, and TIPSS treatment costs. TIPSS was estimated to dominate the comparator for indication 2 (incremental cost and QALYs of − €25,687 and 0.531, respectively). The key drivers of the outcomes were monthly paracentesis sessions and cost per inpatient stay for those undergoing paracentesis. CONCLUSIONS: TIPSS is likely to be a cost-effective and a cost-saving treatment in patients with cirrhosis in indications 1 and 2, compared with standard treatments. The analyses estimate clinical benefits along with reduced healthcare costs from avoided downstream resource consumption. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s12325-023-02517-x. Springer Healthcare 2023-05-09 2023 /pmc/articles/PMC10272260/ /pubmed/37160834 http://dx.doi.org/10.1007/s12325-023-02517-x Text en © The Author(s) 2023 https://creativecommons.org/licenses/by-nc/4.0/Open AccessThis article is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License, which permits any non-commercial use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) . |
spellingShingle | Original Research Bañares, Rafael Albillos, Agustín Nakum, Mitesh Gea, Salvador Varghese, Angel Green, William An Economic Analysis of Transjugular Intrahepatic Portosystemic Covered Stent Shunt for Variceal Bleeding and Refractory Ascites in a Spanish Setting |
title | An Economic Analysis of Transjugular Intrahepatic Portosystemic Covered Stent Shunt for Variceal Bleeding and Refractory Ascites in a Spanish Setting |
title_full | An Economic Analysis of Transjugular Intrahepatic Portosystemic Covered Stent Shunt for Variceal Bleeding and Refractory Ascites in a Spanish Setting |
title_fullStr | An Economic Analysis of Transjugular Intrahepatic Portosystemic Covered Stent Shunt for Variceal Bleeding and Refractory Ascites in a Spanish Setting |
title_full_unstemmed | An Economic Analysis of Transjugular Intrahepatic Portosystemic Covered Stent Shunt for Variceal Bleeding and Refractory Ascites in a Spanish Setting |
title_short | An Economic Analysis of Transjugular Intrahepatic Portosystemic Covered Stent Shunt for Variceal Bleeding and Refractory Ascites in a Spanish Setting |
title_sort | economic analysis of transjugular intrahepatic portosystemic covered stent shunt for variceal bleeding and refractory ascites in a spanish setting |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10272260/ https://www.ncbi.nlm.nih.gov/pubmed/37160834 http://dx.doi.org/10.1007/s12325-023-02517-x |
work_keys_str_mv | AT banaresrafael aneconomicanalysisoftransjugularintrahepaticportosystemiccoveredstentshuntforvaricealbleedingandrefractoryascitesinaspanishsetting AT albillosagustin aneconomicanalysisoftransjugularintrahepaticportosystemiccoveredstentshuntforvaricealbleedingandrefractoryascitesinaspanishsetting AT nakummitesh aneconomicanalysisoftransjugularintrahepaticportosystemiccoveredstentshuntforvaricealbleedingandrefractoryascitesinaspanishsetting AT geasalvador aneconomicanalysisoftransjugularintrahepaticportosystemiccoveredstentshuntforvaricealbleedingandrefractoryascitesinaspanishsetting AT vargheseangel aneconomicanalysisoftransjugularintrahepaticportosystemiccoveredstentshuntforvaricealbleedingandrefractoryascitesinaspanishsetting AT greenwilliam aneconomicanalysisoftransjugularintrahepaticportosystemiccoveredstentshuntforvaricealbleedingandrefractoryascitesinaspanishsetting AT banaresrafael economicanalysisoftransjugularintrahepaticportosystemiccoveredstentshuntforvaricealbleedingandrefractoryascitesinaspanishsetting AT albillosagustin economicanalysisoftransjugularintrahepaticportosystemiccoveredstentshuntforvaricealbleedingandrefractoryascitesinaspanishsetting AT nakummitesh economicanalysisoftransjugularintrahepaticportosystemiccoveredstentshuntforvaricealbleedingandrefractoryascitesinaspanishsetting AT geasalvador economicanalysisoftransjugularintrahepaticportosystemiccoveredstentshuntforvaricealbleedingandrefractoryascitesinaspanishsetting AT vargheseangel economicanalysisoftransjugularintrahepaticportosystemiccoveredstentshuntforvaricealbleedingandrefractoryascitesinaspanishsetting AT greenwilliam economicanalysisoftransjugularintrahepaticportosystemiccoveredstentshuntforvaricealbleedingandrefractoryascitesinaspanishsetting |